Dr. Ralph Lipp will become the founding member of The Catalent Applied Drug Delivery Institute’s advisory board. Dr. Lipp has more than 20 years of industry and academic experience, having previously served as vice president of Pharmaceutical Sciences R&D at Eli Lilly and Co., and in R&D leadership roles at Schering AG. Dr. Lipp’s accomplishments include more than 20 patents, including five marketed medicines and more than 100 additional scientific publications. His research experience includes oncology, cardiovascular disease, central nervous system disorders, women’s health, in vivo diagnostics, and dermatology.
Terry Robinson has been appointed executive director to the Institute. Mrs. Robinson joined Catalent Pharma Solutions five years ago and has fostered numerous collaborations with top pharmaceutical innovators. She has more than 25 years of health care experience at Eli Lilly and Co. and Amgen. Ms. Robinson will work closely with the Institute’s advisory board to advance the use of drug delivery technologies to bring better treatments to patients via new technology development, increased cross-industry and academic collaborations, advanced industry education, research and publications.
“The welcome additions of Dr. Lipp and Ms. Robinson are a significant step in building a strong foundation for the Institute,” said Dr. Kurt Nielsen, a director of the Institute and Catalent’s senior vice president of R&D. “Terry’s ability to build collaborative partnerships, combined with the well-known drug development and delivery expertise of Dr. Lipp and other future advisory board members, will enable the Institute advance the future of drug delivery to improve patient treatments.”